Product logins

Find logins to all Clarivate products below.


EU5 Market Access Opportunities and Barriers for Outpatient Parenteral Antibiotic Therapy| Physician & Payer Forum | EU5 | 2015

Outpatient parenteral antimicrobial therapy (OPAT) is a convenient mechanism for treating patients with infections that require intravenous (IV) antibiotic drugs but are clinically stable and do not otherwise require hospitalization. In addition to improved convenience, OPAT offers distinct advantages over inpatient treatment, such as the potential to reduce healthcare costs and decrease the risk of complications due to prolonged hospitalization. Nonetheless, in contrast to its widespread use in the United States, the OPAT treatment modality has been slower to gain traction in the EU5. However, given that the reduction of treatment costs associated with inpatient antibiotic therapy can be a key driver of OPAT prescribing, commercial opportunity exists for novel antibiotics that can increase OPAT use via improvements in efficacy, safety, and delivery over currently available parenteral drugs.

Related Market Assessment Reports

Report
Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)
Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…
Report
Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…